Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Apremilast - Amgen

Next Previous
Drug Profile

Apremilast - Amgen

Alternative Names: AMG-407; CC-10004; CC-1004; OTEZLA

Latest Information Update: 14 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celgene Corporation
  • Developer Amgen; Baylor Research Institute; Celgene Corporation; Erasmus MC
  • Class Acetamides; Anti-inflammatories; Antiasthmatics; Antineoplastics; Antipsoriatics; Antirheumatics; Antivirals; Isoindoles; Phthalimides; Skin disorder therapies; Small molecules; Sulfones
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Behcet's syndrome; Ulcerative colitis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Behcet's syndrome; Plaque psoriasis; Psoriatic arthritis
  • Phase III Ankylosing spondylitis; COVID 2019 infections; Immunological disorders; Juvenile rheumatoid arthritis; Palmoplantar pustulosis; Psoriasis
  • Phase II Atopic dermatitis; Bullous pemphigoid; Eczema; Female genital diseases; Hidradenitis suppurativa; Ulcerative colitis
  • No development reported Rheumatoid arthritis
  • Discontinued Asthma; Cancer; Crohn's disease

Most Recent Events

  • 09 Mar 2024 Efficacy and safety data from phase III trial in Palmoplantar pustulosis released by Amgen
  • 09 Mar 2024 Updated efficacy results from the phase III SPROUT trial in Plaque psoriasis released by Amgen
  • 11 Dec 2023 Amgen initiates the phase-III ESSENCE trial for Plaque psoriasis in China (PO) (NCT06122649)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top